Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Expenses: 2018-2024

Historic Operating Expenses for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to $324.7 million.

  • Phathom Pharmaceuticals' Operating Expenses fell 30.91% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.9 million, marking a year-over-year increase of 10.34%. This contributed to the annual value of $324.7 million for FY2024, which is 93.50% up from last year.
  • According to the latest figures from FY2024, Phathom Pharmaceuticals' Operating Expenses is $324.7 million, which was up 93.50% from $167.8 million recorded in FY2023.
  • Over the past 5 years, Phathom Pharmaceuticals' Operating Expenses peaked at $324.7 million during FY2024, and registered a low of $125.7 million during FY2020.
  • Over the past 3 years, Phathom Pharmaceuticals' median Operating Expenses value was $172.4 million (recorded in 2022), while the average stood at $221.7 million.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Operating Expenses dropped by 2.68% in 2023, and later surged by 93.50% in 2024.
  • Over the past 5 years, Phathom Pharmaceuticals' Operating Expenses (Yearly) stood at $125.7 million in 2020, then grew by 7.49% to $135.1 million in 2021, then grew by 27.66% to $172.4 million in 2022, then decreased by 2.68% to $167.8 million in 2023, then spiked by 93.50% to $324.7 million in 2024.